Calypso Biotech

Developer of antibody-based therapeutics for the treatment of gastrointestinal diseases

placePlan Les Ouates, Geneva, Switzerland calendar_todayFounded 2013 groups12 employees language calypsobiotech.com

Investor mix

6 investors on record; lead investors include Gilde Healthcare, Johnson & Johnson Innovation, M Ventures, Inkef; 1 has since exited.

Investor typeCountShare
Venture capital350%
Private equity117%
Accelerator & incubator117%
Other / undisclosed117%
Coming soon